Drug Trial Radar · NCT07181148
A Study to Evaluate the Safety and Effectiveness of MSP01-T for Bowel Cleansing Before a Colonoscopy
Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
214
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Mar 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Mather's Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the safety and effectiveness of MSP01-T, a new bowel cleansing agent, in adults who are scheduled to undergo a colonoscopy. Participants will be randomly assigned to receive either MSP01-T or a comparator product. The study will assess how effectively MSP01-T cleans the bowel before the procedure and monitor any potential side effects. Adults aged 19 years and older who are planning to have a colonoscopy may be eligible to take part.
Conditions
- Colonoscopy
- Bowel Preparation
Interventions
MSP01-RDrug
Total 20 tablets, split-dose administration over 2 days: 14 tablets the day before colonoscopy, 14 tablets on the morning of colonoscopy, oral intake.
MSP01-TDrug
Total 20 tablets, split-dose administration over 2 days: 10 tablets the day before colonoscopy, 10 tablets on the morning of colonoscopy, oral intake.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with "successful" bowel cleansing based on HCS [by independent central reader]Time frame: During colonoscopy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk Samsung Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.